Recombinant IL-2 (rIL-2) has been used alone or in combination with other chemotherapeutic agents to enhance host defences against cancer. Prolonged administration of high doses, required for clinical efficacy, may precipitate serious dose-limiting toxicity. rIL-2-induced 'vascular leak syndrome' leads to hypotension, renal insufficiency, respiratory disturbances and other organ dysfunctions. Serial measurements of serum cytokines and the acute phase protein C-reactive protein (CRP) were performed on nine patients who received high-dose i.v. continuous therapy with rIL-2. The influence of these immunological parameters upon alterations in patients' weight and serum albumin, as indicators of toxicity, was assessed. All patients experienced weight increases during the cycle (3-11% of total body weight). The serum levels of tumour necrosis factor (TNF-α) and CRP were highly predictive of alterations in patients' weight (both P <0.001), while no correlation was found with IL-6 and weight change. Serum albumin fell linearly throughout the infusion cycle, but this showed no correlation with variations in serum levels of IL-6, TNF-α, or CRP. The complement components C3 and C4 were significantly reduced at the end of the infusion, suggesting a possible role for this cascade system in mediating these clinical changes. The strong association between serum TNF-α and weight change, not previously documented, further supports the hypothesis that TNF-α is a key mediator in the pathogenesis of the 'vascular leak syndrome'.
CITATION STYLE
Deehan, D. J., Heys, S. D., Simpson, W., Herriot, R., Broom, J., & Eremin, O. (1994). Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2. Clinical and Experimental Immunology, 95(3), 366–372. https://doi.org/10.1111/j.1365-2249.1994.tb07005.x
Mendeley helps you to discover research relevant for your work.